BioTime Investor Day
BioTime, Inc. is pleased to invite you to attend a unique forum featuring in depth presentations from the Company’s key collaborators and subsidiaries. A keynote address will be presented by BioTime and OncoCyte Board member, Andrew von Eschenbach, M.D., former FDA Commissioner and Director of the National Cancer Institute.
Monday, April 23, 2012
2:00PM – 6:15PM with cocktail reception to follow
Harvard Club of New York City, Biddle Room
27 W.44th Street, New York, NY (between 5th & 6th Avenues)
PRESENTING SUBSIDIARIES:
- Cell Cure NeuroSciences, Ltd. - Leading supplier of therapeutic cells for the treatment of retinal and neural degenerative disease. OpRegen™ cell therapy platform utilizes proprietary technology that drives differentiation of human embryonic stem cells into retinal pigment epithelial (RPE) cells.
- OncoCyte Corporation – Oncology-focused diagnostics company leveraging embryonic stem cell-derived technology in order to provide earlier detection and improve patients’ quality and length of life by specifically removing malignant tumors without affecting nearby normal body tissue.
- OrthoCyte Corporation – Developer of cellular therapeutics for orthopedic disorders. The division’s lead project is the development of human embryonic progenitor (hEP) cell lines for cartilage repair, including osteoarthritis.
- ReCyte Therapeutics, Inc. – Developer of therapeutics for cardiovascular and blood diseases based on its ReCyte™ iPS technology. This platform reverses the developmental aging of human cells and generates embryonic vascular and blood progenitors from the ReCyte cell lines for therapeutic use in age-related vascular and blood disorders, such as coronary disease and heart failure.
- LifeMap Sciences, Inc. – Developer of a discovery platform, including a web-based database, to aid R&D efforts in the stem cells field, using embryonic stem cells, progenitor cells, induced pluripotent stem cells and other relevant cell types.
- BioTime Asia, Ltd. – Developer and marketer of BioTime stem cell technology within Asian geographies, with a particular focus within China. The Asian region offers significant developmental advantages, such as dense patient populations, flexible regulation and public acceptance, and abbreviated clinical application timelines.